Immunotherapy advances in triple-negative breast cancer drive personalized treatments with immune checkpoint inhibitors, ...

Finance News; EMV Capital investee initiates phase 3 trial for head and neck cancer; EMV Capital investee initiates phase 3 trial for head and neck cancer ...

We are thrilled to share that the first trial site has been initiated and activation of additional clinical sites continues,” said Frank Bedu-Addo, PhD, President and Chief Executive Officer of PDS ...

While this pembrolizumab-based regimen is promising and much needed in this patient population, one should remain cognizant of its high costs and the subsequent impact this may have on patients and ...

ALX Oncology Holdings Inc.’s ALXO share price has dipped by 19.08%, which has investors questioning if this is right time to buy.

Discover a study where results suggest trends towards overall survival and progression-free survival improvements with ...

Topline interim dataset from GALAXIES Lung-201 with >240 patients anticipated in 2Q25- Interim datasets from GALAXIES H&N-202 and ...

The US Food and Drug Administration has approved tislelizumab (Tevimbra, BeiGene), in combination with platinum-containing ...

VIR's T-cell engagers have potential in oncology and showed promise with initial data in January 2025. Read my thoughts about ...

A personalized vaccine demonstrated the potential to induce long-lasting immune response among people with advanced kidney ...

Despite a proven survival benefit, the addition of pembrolizumab (Keytruda) to chemoradiotherapy for newly diagnosed locally ...

The Jha brothers are accused of trafficking in various falsified medicines, including knock-offs of Merck & Co's Keytruda.